Breaking News, Collaborations & Alliances

RedHill and Cosmo Expand Opaganib Manufacturing Deal

New agreement expands manufacturing capacity for orally-administered opaganib following positive top-line data from its Phase 2 COVID-19 study.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RedHill Biopharma, a specialty biopharmaceutical company, has formed a manufacturing agreement with Cosmo Pharmaceuticals to further expand manufacturing capacity for opaganib to address prospective demand subsequent to potential global emergency use authorizations.   “The growing concerns over viral mutations and the spread of new potent and evasive viral strains have increased the dire need for new COVID-19 therapeutics,” said Reza Fathi, senior vice president, R&D, RedHill. &#...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters